Gray Market Peptides: So Much Hype, So Little Data The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Updates Safety Label for Capecitabine and 5 FU for Risks Associated With DPD Deficiency Oncology Nursing Society In 2023, the FDA deemed 19 peptide drugs too unsafe to be dispensed by compounding pharmacies, which mix components of approved drugs to create bespoke medication for people who have trouble taking The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) FDA